Medical School Renews Contract with Tech Co.

A leading U.S. medical school renewed its contract to use Treatment.com AI Inc.'s (TRUE:CSE; TREIF:OTCMKTS;939:FRA) Medical Education Suite (MES), the company announced in a news release. MES provides case-based clinical decision-making, testing, grading, and remedial action support to empower the healthcare professionals of tomorrow.

"It underpins our focus on the next generation of clinicians, as well as streamlining the operational costs and time currently experienced by medical schools when running the premier exams (Objective Structure Clinical Exams, or OSCEs) designed to test student practical clinical decision-making and reasoning," Chief Executive Officer Dr. Essam Hamza said in the release. Globally, 57 countries use OSCEs.

MES also aims to minimize the administrative work in grading and create a consistent, real-time approach for case testing and scoring.

"To underscore the accuracy of its platform, the company recently announced that a non-medical undergraduate using its artificial intelligence (AI) software passed a medical clinical exam, exceeding a 92% success rate," wrote Technical Analyst Clive Maund in an April 22 report.

Treatment.com AI is in discussions about MES with a number of other medical and nursing schools in the U.S. and internationally, the company noted. The potential to expand this line of business is sizable, given the States is home to 300 medical schools, 900 nursing schools, 227,000 students, and 145,000 residents/medical students.

Products Positively Disrupt Healthcare

With a mission to "dramatically disrupt how healthcare is delivered worldwide," Treatment.com AI develops and provides medical software solutions for students, educators, and clinicians. The Vancouver, British Columbia-based firm continues to expand its pipeline of offerings.

The company "should have a very bright future," wrote Technical Analyst Clive Maund in a February 16 report.

Treatment.com AI's array of products is powered by its proprietary, AI-backed Global Library of Medicine (GLM), created with hundreds of credentialed clinicians worldwide, to ensure the highest qualified clinical information and support are delivered. According to the company, the GLM is "the most comprehensive and integrated online medical library."

Technical Analyst Clive Maund recommended Treatment.com AI as a Strong Buy for all time frames and indicated he planned to stay long in it.

Beyond medical education and working with partners, the company sees its GLM being utilized by an array of enterprises, including Electronic Medical Records, Healthbots/Symptom Checkers, Virtual Health providers, Medical Call Centers, National Triage Services, or Health Information Lines/websites.

 Organizations may integrate with the GLM through an application programming interface (API), thereby allowing them to improve both clinical accuracy and efficiency of their clinical information support and enhancing processes, from back-office tasks to patient intake and care. For healthcare professionals, these include writing medical notes, providing guidance on differential diagnoses with probabilities, suggesting recommended and most important treatments and testing, and determining accurate billing codes.

Sizzling Sector

The healthcare market is rapidly growing around the world, and the use of AI in the space is increasing. As such, AI and healthcare combined are hot sectors, as data from Statista and Market and Markets show.

The global AI healthcare market nearly doubled in value between 2021 and today, going from US$11 billion (US$11B) to US$20.9B. Between now and 2029, the market is expected to increase more than sevenfold, reaching US$148.4B.

This value jump over the next four years represents a compound annual growth rate (CAGR) of 48.1%. CAGRs above 20% in the tech space are considered "excellent," according to Wealthy Education.

"The growth potential of this industry is enormous," Maund wrote. "With Treatment.com AI having already developed its own platform, it is centrally placed to be a part of this."

According to Market and Markets, numerous factors are driving this market expansion. They include "the generation of large and complex healthcare data sets, the pressing need to reduce healthcare costs, improving computing power and declining hardware costs, the rising number of partnerships and collaborations among different domains in the healthcare sector, and the growing need for improvised healthcare services due to imbalance between healthcare workforce and patients."

Catalysts: Additional Product Launches

In H2/24, Treatment.com AI intends to make available two new, monthly, subscription-based, software-as-a-service (SaaS) solutions for students, residents, and other healthcare professionals: AI Patient and AI Doctor in a Pocket.

Unveiled last month, these SaaS products are designed to enhance the training and clinical decision-making capabilities of the users. For the company, these new offerings could increase its revenue and expand its market penetration.

Analyst: Rated Strong Buy

In an April 22 report, Maund asserted that a new technical analysis of Treatment.com AI's stock reveals it to be in a "new bull market" that appears "set not just to continue but to accelerate with the real possibility of spectacular gains ahead." The trading pattern suggests the stock now is completing a small bull flag/pennant shape, an indicator of an impending upleg.

Thus, Maund recommended Treatment.com AI as a Strong Buy for all time frames and indicated he planned to stay long in it.

Ownership and Share Structure

According to Reuters, two insiders own 13.12%, or 4.87 million (4.87M) shares, of Treatment.com AI. They are Chief Medical Officer, Chairman, and Director Dr. Kevin Peterson with 10.35% or 3.84M shares.

Retail investors own the remaining 86.88%. There are no institutional investors currently. 

The company has 39,243,518  million outstanding shares and 25,940,377 free-float traded shares. 

Its market cap is CA$24,330,981, and its 52-week trading range is CA$0.10 to CA$1.20 per share. 

Important Disclosures:

1. Treatment.com AI Inc. has a consulting relationship with an affiliate of Streetwise Reports, and pays a monthly consulting fee between US$8,000 and US$20,000.
2. As of the date of this article, officers and/or employees of Streetwise Reports LLC (including members of their household) own securities of Treatment.com AI Inc.
3. Doresa Banning wrote this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor.
4.  This article does not constitute investment advice and is not a solicitation for any investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Each reader is encouraged to consult with his or her personal financial adviser and perform their own comprehensive investment research. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company. 
5. This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.

For additional disclosures, please click here.

Contributing Author Disclosures

1. Author Certification and Compensation: [Clive Maund of clivemaund.com] is being compensated as an independent contractor by Street Smart, an affiliate of Streetwise Reports, for writing this article. Maund received his UK Technical Analysts’ Diploma in 1989.  The recommendations and opinions expressed in this content accurately reflect the personal, independent, and objective views of the author regarding any and all of the designated securities discussed. No part of the compensation received by the author was, is, or will be directly or indirectly related to the specific recommendations or views expressed

Clivemaund.com Disclosures:

The above represents the opinion and analysis of Mr. Maund, based on data available to him, at the time of writing. Mr. Maund's opinions are his own, and are not a recommendation or an offer to buy or sell securities. As trading and investing in any financial markets may involve serious risk of loss, Mr. Maund recommends that you consult with a qualified investment advisor, one licensed by appropriate regulatory agencies in your legal jurisdiction and do your own due diligence and research when making any kind of a transaction with financial ramifications. Although a qualified and experienced stock market analyst, Clive Maund is not a Registered Securities Advisor. Therefore Mr. Maund's opinions on the market and stocks cannot be  only be construed as a recommendation or solicitation to buy and sell securities.